Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 2, 2003, Pages 347-352

  Van Eldere, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Nosocomial infections; Pseudomonas aeruginosa; Surveillance; Susceptibility rates

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; ISEPAMICIN; LEVOFLOXACIN; MEROPENEM; OFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BELGIUM; CONTROLLED STUDY; DRUG POTENCY; DRUG SURVEILLANCE PROGRAM; HOSPITAL INFECTION; LUXEMBOURG; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 0037326937     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg102     Document Type: Article

References (21)

1. Suetens, C., Jans, B., Carsauw, H. & Ronveaux, O. (1998). Nosocomiale pneumonieën en bacteriëmieën in intensieve zorgen eenheden: resultaten van de Belgische nationale surveillance, 1996-1998. Noso-info II, 58-65.
2. Boffi, E., Chamot, E., Auckenthaler, R., Pechère, J. C. & van Delden, C. (2000). The influence of preceding antibiotic treatments on the resistance profile of Pseudomonas aeruginosa bacteremic strains. Clinical Microbiology and Infection 6, 119.
3. Fridkin, S. K. & Gaynes, R. P. (1999). Antimicrobial resistance in intensive care units. Clinics in Chest Medicine 20, 303-16.
4. Ramirez-Ronda, C. H., Ramirez-Ramirez, C. & Vera, D. (1999). Change in resistance of aerobic Gram-negative bacilli is to β-lactams after cefepime use. In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA. Abstract 1470, p. 163. American Society for Microbiology, Washington, DC, USA.
5. Garbino, J., Loffler, J., Rohner, P., Lew, D. & Auckenthaler, R. (2000). Antibiotic consumption and development of resistance in intensive care units. Clinical Microbiology and Infection 6, Suppl. 1, 46.
6. Verbist, L. (1991) Incidence of multi-resistance in Gram-negative bacterial isolates from intensive care units in Belgium: a surveillance study. Scandinavian Journal of Infectious Diseases Supplementum 78, 45-53.
7. Verbist, L., Verhaegen, J., Wouters, Ch., Vandenhoven, G. & A Multicentre Study Group. (1996). Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalized patients. Journal of Antimicrobial Chemotherapy 37, 285-93.
8. Glupczynski, Y., Delmée, M., Goossens, H. & Struelens, M. on behalf of a Belgian Multicenter ICU study group. (1998). A multicentre survey of antimicrobial resistance in Gram-negative isolates from Belgian intensive care units in 1994-1995. Acta Clinica Belgica 53, 28-38.
9. Glupczynski, Y., Delmée, M., Goossens, H., Struelens, M. & Van Landuyt, H. (1999). Comparative in vitro activity of isepamicin and other antibiotic against Gram-negative bacilli from ICU patients in Belgium. In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA. Abstract 63, p. 241. American Society for Microbiology, Washington, DC, USA.
10. Piérard, D., Emmerechts, K., Lauwers, S. & A Belgian Multicentre Study Group (1998). Comparative in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology units. Journal of Antimicrobial Chemotherapy 41, 443-50.
11. Groupe d'Etude de la Résistance de P. aeruginosa aux Bêtalactamines (GERPB). (2000). Evolution de la résistance aux antibiotiques de Pseudomonas aeruginosa en France de 1994 à 1998. Lettre de l'Infectiologue XV, 18-23.
12. Bouza, E., Garcia-Garrote, F., Cercenado, E., Marin, M. & Diaz, M. S. for The Spanish Pseudomonas aeruginosa Study Group. (1999). Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. Antimicrobial Agents and Chemotherapy 43, 981-2.
13. Bonfiglio, G., Carciotto, V., Russo, G., Stefani, S., Schito, G. C., Debbia, E. et al. (1998). Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey. Journal of Antimicrobial Chemotherapy 41, 307-10.
14. Basustaoglu, A. C., Gun, H., Sarachi, M. A., Baysallar, M. & Haznedaroglu, T. (1995). Development of resistance to imipenem among nosocomial isolates of Pseudomonas aeruginosa. European Journal of Clinical Microbiology and Infectious Diseases 14, 469-70.
15. Carmeli, Y., Troillet, N., Eliopoulos, G. M. & Samore, M. H. (1999). Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrobial Agents and Chemotherapy 43, 1379-82.
16. Köhler, T., Michea-Hamzehpour, M., Epp, S. F. & Pechère, J.-C. (1999). Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrobial Agents and Chemotherapy 43, 424-7.
17. Ziha-Zarifi, I., Llanes, C., Köhler, T., Pechère, J. C. & Plesiat, P. (1999). In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrobial Agents and Chemotherapy 43, 287-91.
18. Bonfiglio, G. & Marchetti, F. (2000). In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams. Chemotherapy 46, 229-34.
19. Allouch, P., Chardon, H., Rio, Y., Auvray, C., Bietrix, M., Chaplain, C. et al. (1999). French survey of antibiotic susceptibility of pathogens responsible for infections in intensive care units. Clinical Microbiology and Infection 5, Suppl. 3, 239.
20. Bert, F., Briaud, I., Branger, C. & Lambert-Zechovsky, N. (1996). Comparaison de l'activité des β-lactamines sur Pseudomonas aeruginosa en fonction des phénotypes de résistance. Pathologie et Biologie 44, 329-32.
21. Köhler, T., Michea-Hamzehpour, M., Plesiat, P., Kahr, A.-L. & Pechère, J.-C. (1997). Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 41, 2540-3.